{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:56:12Z","timestamp":1794657372298,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alberta Innovates \u2013ASBIRI Program","award":["G2017000328"],"award-info":[{"award-number":["G2017000328"]}]},{"name":"Alberta Innovates \u2013ASBIRI Program","award":["G2017000328"],"award-info":[{"award-number":["G2017000328"]}]},{"name":"Alberta Innovates \u2013ASBIRI Program","award":["G2017000328"],"award-info":[{"award-number":["G2017000328"]}]},{"name":"Alberta Innovates \u2013ASBIRI Program","award":["G2017000328"],"award-info":[{"award-number":["G2017000328"]}]},{"name":"Alberta Innovates \u2013ASBIRI Program","award":["G2017000328"],"award-info":[{"award-number":["G2017000328"]}]},{"name":"Bird Dogs - Alberta Cancer Foundation: Prostate Cancer Research Plan","award":["ACF 26001"],"award-info":[{"award-number":["ACF 26001"]}]},{"name":"Bird Dogs - Alberta Cancer Foundation: Prostate Cancer Research Plan","award":["ACF 26001"],"award-info":[{"award-number":["ACF 26001"]}]},{"name":"Bird Dogs - Alberta Cancer Foundation: Prostate Cancer Research Plan","award":["ACF 26001"],"award-info":[{"award-number":["ACF 26001"]}]},{"name":"Bird Dogs - Alberta Cancer Foundation: Prostate Cancer Research Plan","award":["ACF 26001"],"award-info":[{"award-number":["ACF 26001"]}]},{"name":"Bird Dogs - Alberta Cancer Foundation: Prostate Cancer Research Plan","award":["ACF 26001"],"award-info":[{"award-number":["ACF 26001"]}]},{"name":"TELUS Ride for Dad and the Prostate Cancer Fight Foundation"},{"DOI":"10.13039\/501100000109","name":"Prostate Cancer Canada","doi-asserted-by":"publisher","award":["PCC MTA TAG2014-03"],"award-info":[{"award-number":["PCC MTA TAG2014-03"]}],"id":[{"id":"10.13039\/501100000109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000109","name":"Prostate Cancer Canada","doi-asserted-by":"publisher","award":["PCC MTA TAG2014-03"],"award-info":[{"award-number":["PCC MTA TAG2014-03"]}],"id":[{"id":"10.13039\/501100000109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000109","name":"Prostate Cancer Canada","doi-asserted-by":"publisher","award":["PCC MTA TAG2014-03"],"award-info":[{"award-number":["PCC MTA TAG2014-03"]}],"id":[{"id":"10.13039\/501100000109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000109","name":"Prostate Cancer Canada","doi-asserted-by":"publisher","award":["PCC MTA TAG2014-03"],"award-info":[{"award-number":["PCC MTA TAG2014-03"]}],"id":[{"id":"10.13039\/501100000109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000109","name":"Prostate Cancer Canada","doi-asserted-by":"publisher","award":["PCC MTA TAG2014-03"],"award-info":[{"award-number":["PCC MTA TAG2014-03"]}],"id":[{"id":"10.13039\/501100000109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This prognostic study created optimized ensembles of calibrated random forest models to predict clinically significant prostate cancer (csPCa, grade group \u22652\u2009PCa) using total prostate-specific antigen (PSA), free PSA, negative biopsy status, and age, with or without DRE and MRI data. Observational data were aggregated from cohorts in six organizations in Canada, the USA, and Czechia. Prostate biopsies were performed between 2009 and 2024. Risk models (ClarityDX Prostate\u2009+\u2009DRE, ClarityDX Prostate\u2009+\u2009MRI, and ClarityDX Prostate\u2009+\u2009MRI\u2009+\u2009DRE) were derived (training cohorts\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091626 to 2191) and validated (validation cohorts\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009378 to 1318) from different clinical sites. The models had ROC AUC values\u2009\u2265\u20090.80. Adding DRE improved the ROC AUC to 0.82 while models using MRI features had ROC AUC values of 0.87 (without DRE) and 0.88 (with DRE) in the validation cohort. These four ClarityDX Prostate models offer high accuracy in predicting csPCa in individuals in variable clinical settings.\n                  <\/jats:p>","DOI":"10.1038\/s41746-026-02642-1","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:54:33Z","timestamp":1776412473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predicting clinically significant prostate cancer with or without digital rectal exam and MRI data using ClarityDX Prostate models"],"prefix":"10.1038","volume":"9","author":[{"given":"Robert J.","family":"Paproski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kinnaird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Eric","family":"Hyndman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Fairey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian P.","family":"Pavlovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean A.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Zachoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Adamcova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Stejskal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armen","family":"Aprikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J. D.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"Pink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Vasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrin H.","family":"Beatty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"2642_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2642_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-55859-z","volume":"14","author":"PW McLaughlin","year":"2024","unstructured":"McLaughlin, P. W., Cousins, M. M., Tsodikov, A., Soni, P. D. & Crook, J. M. Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era. Sci. Rep. 14, 5810 (2024).","journal-title":"Sci. Rep."},{"key":"2642_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/jnci\/djaa068","volume":"113","author":"A Jemal","year":"2020","unstructured":"Jemal, A., Culp, M. B., Ma, J., Islami, F. & Fedewa, S. A. Prostate cancer incidence 5 years after US Preventive Services Task Force recommendations against screening. J. Natl. Cancer Inst. 113, 64\u201371 (2020).","journal-title":"J. Natl. Cancer Inst."},{"key":"2642_CR4","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41585-022-00638-6","volume":"19","author":"H Van Poppel","year":"2022","unstructured":"Van Poppel, H. et al. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat. Rev. Urol. 19, 562\u2013572 (2022).","journal-title":"Nat. Rev. Urol."},{"key":"2642_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","volume":"69","author":"JI Epstein","year":"2016","unstructured":"Epstein, J. I. et al. A contemporary prostate cancer grading system: a validated alternative to the gleason score. Eur. Urol. 69, 428\u2013435 (2016).","journal-title":"Eur. Urol."},{"key":"2642_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JU.0000000000003491","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei, J. T. et al. Early detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening. J. Urol. 210, 46\u201353 (2023).","journal-title":"J. Urol."},{"key":"2642_CR7","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2642_CR8","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3390\/cancers14061589","volume":"14","author":"J Morote","year":"2022","unstructured":"Morote, J. et al. The Barcelona predictive model of clinically significant prostate cancer. Cancers 14, 1589 (2022).","journal-title":"Cancers"},{"key":"2642_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.21037\/tau.2017.04.31","volume":"6","author":"CJD Wallis","year":"2017","unstructured":"Wallis, C. J. D., Haider, M. A. & Nam, R. K. Role of mpMRI of the prostate in screening for prostate cancer. Transl. Androl. Urol. 6, 464\u2013471 (2017).","journal-title":"Transl. Androl. Urol."},{"key":"2642_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41585-019-0212-4","volume":"17","author":"A Stabile","year":"2019","unstructured":"Stabile, A. et al. Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nat. Rev. Urol. 17, 41\u201361 (2019).","journal-title":"Nat. Rev. Urol."},{"key":"2642_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.eururo.2018.07.031","volume":"75","author":"AR Alberts","year":"2019","unstructured":"Alberts, A. R. et al. Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the Rotterdam European Randomised Study of screening for prostate cancer risk calculators. Eur. Urol. 75, 310\u2013318 (2019).","journal-title":"Eur. Urol."},{"key":"2642_CR12","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1001\/jamaoncol.2018.4160","volume":"4","author":"SJ Kim","year":"2018","unstructured":"Kim, S. J., Vickers, A. J. & Hu, J. C. Challenges in adopting level 1 evidence for multiparametric magnetic resonance imaging as a biomarker for prostate cancer screening. JAMA Oncol. 4, 1663\u20131664 (2018).","journal-title":"JAMA Oncol."},{"key":"2642_CR13","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.eururo.2013.12.012","volume":"66","author":"M de Rooij","year":"2014","unstructured":"de Rooij, M. et al. Cost-effectiveness of magnetic resonance (MR) imaging and mr-guided targeted biopsy versus systematic transrectal ultrasound\u2013guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. Eur. Urol. 66, 430\u2013436 (2014).","journal-title":"Eur. Urol."},{"key":"2642_CR14","first-page":"e40625","volume":"15","author":"M Teoh","year":"2023","unstructured":"Teoh, M., Lee, D., Cooke, D. & Nyandoro, M. G. Digital rectal examination: perspectives on current attitudes, enablers, and barriers to its performance by doctors-in-training. Cureus 15, e40625 (2023).","journal-title":"Cureus"},{"key":"2642_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1200\/JCO.2019.37.7_suppl.48","volume":"37","author":"JM Andersson","year":"2019","unstructured":"Andersson, J. M., Nordstr\u00f6m, T., Eklund, M. & Gronberg, H. The predictive value of DRE in the modern era of prostate cancer diagnostics. J. Clin. Oncol. 37, 48\u201348 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2642_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12245-018-0165-z","volume":"11","author":"J Quinn","year":"2018","unstructured":"Quinn, J., Zeleny, T., Rajaratnam, V., Ghiurluc, D. L. & Bencko, V. Debate: the per rectal\/digital rectal examination exam in the emergency department, still best practice? Int J. Emerg. Med. 11, 20 (2018).","journal-title":"Int J. Emerg. Med."},{"key":"2642_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ucl.2015.08.001","volume":"43","author":"A Lepor","year":"2016","unstructured":"Lepor, A., Catalona, W. J. & Loeb, S. The prostate health index: its utility in prostate cancer detection. Urol. Clin. North Am. 43, 1\u20136 (2016).","journal-title":"Urol. Clin. North Am."},{"key":"2642_CR18","doi-asserted-by":"publisher","unstructured":"Vickers, A. J., Vertosick, E. A. & Sjoberg, D. D. Value of a statistical model based on four kallikrein markers in blood, commercially available as 4Kscore, in all reasonable prostate biopsy subgroups. Eur. Urol. 74, https:\/\/doi.org\/10.1016\/j.eururo.2018.05.032 (2018).","DOI":"10.1016\/j.eururo.2018.05.032"},{"key":"2642_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2018.05.003","volume":"74","author":"DP Ankerst","year":"2018","unstructured":"Ankerst, D. P. et al. A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts. Eur. Urol. 74, 197\u2013203 (2018).","journal-title":"Eur. Urol."},{"key":"2642_CR20","doi-asserted-by":"publisher","unstructured":"Desai, C., Ehsanullah, S. A., Bhojwani, A. & Dhanasekaran, A. 648\u2003External validation of The European Randomized Study of Screening for Prostate Cancer Risk Calculator 3 (ERSPC-RC3) in the detection of prostate cancer and avoiding unnecessary prostate biopsies. Br. J. Surg. 108, https:\/\/doi.org\/10.1093\/bjs\/znab134.566 (2021).","DOI":"10.1093\/bjs\/znab134.566"},{"key":"2642_CR21","first-page":"E161","volume":"16","author":"A Kinnaird","year":"2022","unstructured":"Kinnaird, A. et al. A prostate cancer risk calculator: Use of clinical and magnetic resonance imaging data to predict biopsy outcome in North American men. Can. Urol. Assoc. J. 16, E161\u2013e166 (2022).","journal-title":"Can. Urol. Assoc. J."},{"key":"2642_CR22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jamaoncol.2017.5667","volume":"4","author":"S Mehralivand","year":"2018","unstructured":"Mehralivand, S. et al. A magnetic resonance imaging-based prediction model for prostate biopsy risk stratification. JAMA Oncol. 4, 678\u2013685 (2018).","journal-title":"JAMA Oncol."},{"key":"2642_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bju.15835","volume":"131","author":"HD Patel","year":"2023","unstructured":"Patel, H. D. et al. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators. BJU Int. 131, 227\u2013235 (2023).","journal-title":"BJU Int."},{"key":"2642_CR24","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/bju.13814","volume":"120","author":"PJ van Leeuwen","year":"2017","unstructured":"van Leeuwen, P. J. et al. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. BJU Int. 120, 774\u2013781 (2017).","journal-title":"BJU Int."},{"key":"2642_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.euros.2022.04.017","volume":"41","author":"S Parekh","year":"2022","unstructured":"Parekh, S. et al. The Mount Sinai prebiopsy risk calculator for predicting any prostate cancer and clinically significant prostate cancer: development of a risk predictive tool and validation with advanced neural networking, prostate magnetic resonance imaging outcome database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator. Eur. Urol. open Sci. 41, 45\u201354 (2022).","journal-title":"Eur. Urol. open Sci."},{"key":"2642_CR26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.eururo.2011.11.012","volume":"61","author":"MJ Roobol","year":"2012","unstructured":"Roobol, M. J. et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur. Urol. 61, 577\u2013583 (2012).","journal-title":"Eur. Urol."},{"key":"2642_CR27","doi-asserted-by":"publisher","first-page":"831.e819","DOI":"10.1016\/j.urolonc.2021.06.004","volume":"39","author":"NN Wang","year":"2021","unstructured":"Wang, N. N. et al. The Stanford Prostate Cancer Calculator: development and external validation of online nomograms incorporating PIRADS scores to predict clinically significant prostate cancer. Urol. Oncol. 39, 831.e819\u2013831.e827 (2021).","journal-title":"Urol. Oncol."},{"key":"2642_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-024-01167-9","volume":"7","author":"ME Hyndman","year":"2024","unstructured":"Hyndman, M. E. et al. Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform. npj Digit. Med. 7, 163 (2024).","journal-title":"npj Digit. Med."},{"key":"2642_CR29","volume":"6","author":"VG Wagaskar","year":"2023","unstructured":"Wagaskar, V. G. et al. A SelectMDx\/magnetic resonance imaging-based nomogram to diagnose prostate cancer. Cancer Rep. 6, e1668 (2023).","journal-title":"Cancer Rep."},{"key":"2642_CR30","volume":"4","author":"VG Wagaskar","year":"2021","unstructured":"Wagaskar, V. G. et al. A 4K score\/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer. Cancer Rep. 4, e1357 (2021).","journal-title":"Cancer Rep."},{"key":"2642_CR31","unstructured":"NCCN_Guidelines. Prostate Cancer Early Detection Version 1.2025, https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=2&id=1460 (2025)."},{"key":"2642_CR32","doi-asserted-by":"publisher","first-page":"7742","DOI":"10.1002\/cam4.3395","volume":"9","author":"AM Getaneh","year":"2020","unstructured":"Getaneh, A. M., Heijnsdijk, E. A., Roobol, M. J. & de Koning, H. J. Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: a micro-simulation study of 230 scenarios. Cancer Med. 9, 7742\u20137750 (2020).","journal-title":"Cancer Med."},{"key":"2642_CR33","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/jnci\/dju366","volume":"107","author":"EA Heijnsdijk","year":"2015","unstructured":"Heijnsdijk, E. A. et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J. Natl. Cancer Inst. 107, 366 (2015).","journal-title":"J. Natl. Cancer Inst."},{"key":"2642_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/JU.0000000000003492","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei, J. T. et al. Early detection of prostate cancer: AUA\/SUO guideline part II: considerations for a prostate biopsy. J. Urol. 210, 54\u201363 (2023).","journal-title":"J. Urol."},{"key":"2642_CR35","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3390\/clinpract14020039","volume":"14","author":"E Bologna","year":"2024","unstructured":"Bologna, E. et al. Tissue-based genomic testing in prostate cancer: 10-year analysis of national trends on the use of Prolaris, Decipher, ProMark, and Oncotype DX. Clin. Pract. 14, 508\u2013520 (2024).","journal-title":"Clin. Pract."},{"key":"2642_CR36","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.eururo.2018.08.019","volume":"74","author":"J McKiernan","year":"2018","unstructured":"McKiernan, J. et al. A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2\u201310 ng\/ml at initial biopsy. Eur. Urol. 74, 731\u2013738 (2018).","journal-title":"Eur. Urol."},{"key":"2642_CR37","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1001\/jamaoncol.2016.0097","volume":"2","author":"J McKiernan","year":"2016","unstructured":"McKiernan, J. et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2, 882\u2013889 (2016).","journal-title":"JAMA Oncol."},{"key":"2642_CR38","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.euo.2023.07.006","volume":"6","author":"J Freds\u00f8e","year":"2023","unstructured":"Freds\u00f8e, J. et al. Results from the PRIMA trial: comparison of the STHLM3 test and prostate-specific antigen in general practice for detection of prostate cancer in a biopsy-na\u00efve population. Eur. Urol. Oncol. 6, 484\u2013492 (2023).","journal-title":"Eur. Urol. Oncol."},{"key":"2642_CR39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1200\/JCO.2024.42.4_suppl.262","volume":"42","author":"HT Vigneswaran","year":"2024","unstructured":"Vigneswaran, H. T. et al. Stockholm3 validation in a multi-ethnic cohort for prostate cancer (SEPTA) detection: a multicentered, prospective trial. J. Clin. Oncol. 42, 262\u2013262 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2642_CR40","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.euf.2023.09.016","volume":"10","author":"A Elyan","year":"2024","unstructured":"Elyan, A. et al. Prospective multicenter validation of the Stockholm3 test in a Central European Cohort. Eur. Urol. focus 10, 620\u2013626 (2024).","journal-title":"Eur. Urol. focus"},{"key":"2642_CR41","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","volume":"402","author":"D Schrag","year":"2023","unstructured":"Schrag, D. et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet 402, 1251\u20131260 (2023).","journal-title":"Lancet"},{"key":"2642_CR42","first-page":"373","volume":"79","author":"A World Medical","year":"2001","unstructured":"World Medical, A. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull. World Health Organ. 79, 373\u2013374 (2001).","journal-title":"Bull. World Health Organ."},{"key":"2642_CR43","doi-asserted-by":"publisher","first-page":"e037222","DOI":"10.1136\/bmjopen-2020-037222","volume":"10","author":"C Vasquez","year":"2020","unstructured":"Vasquez, C. et al. Cohort profile: the Alberta Prostate Cancer Research Initiative (APCaRI) registry and biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada. BMJ Open 10, e037222 (2020).","journal-title":"BMJ Open"},{"key":"2642_CR44","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.eururo.2017.03.039","volume":"72","author":"JP Radtke","year":"2017","unstructured":"Radtke, J. P. et al. Combined clinical parameters and multiparametric magnetic resonance imaging for advanced risk modeling of prostate cancer\u2014patient-tailored risk stratification can reduce unnecessary biopsies. Eur. Urol. 72, 888\u2013896 (2017).","journal-title":"Eur. Urol."},{"key":"2642_CR45","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.eururo.2022.07.022","volume":"82","author":"M Peters","year":"2022","unstructured":"Peters, M. et al. Predicting the need for biopsy to detect clinically significant prostate cancer in patients with a magnetic resonance imaging\u2013detected prostate imaging reporting and data system\/Likert\u22653 lesion: development and multinational external validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score. Eur. Urol. 82, 559\u2013568 (2022).","journal-title":"Eur. Urol."},{"key":"2642_CR46","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.urology.2014.02.035","volume":"83","author":"DP Ankerst","year":"2014","unstructured":"Ankerst, D. P. et al. Prostate cancer prevention trial risk calculator 2.0 for the prediction of low- versus high-grade prostate cancer. Urology 83, 1362\u20131368 (2014).","journal-title":"Urology"},{"key":"2642_CR47","doi-asserted-by":"crossref","unstructured":"DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837\u2013845 (1988).","DOI":"10.2307\/2531595"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02642-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:05:19Z","timestamp":1781654719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02642-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2642"],"URL":"https:\/\/doi.org\/10.1038\/s41746-026-02642-1","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that M.E.H., A.F., and C.J.W. are Nanostics consultants. A.A. is a Nanostics board member. R.J.P, D.P, C.V., P.H.B., and J.D.L. are Nanostics employees. All other authors have no competing interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"467"}}